Day: September 18, 2024

Mondelēz International Makes Progress Toward Packaging Goals with Advanced Recycling Technology in Triscuit Packaging*

Written by Customer Service on September 18, 2024. Posted in Public Companies.

Advanced recycling technology enables recycled plastic to transform into new cracker packaging* EAST HANOVER, N.J., Sept. 18, 2024 (GLOBE NEWSWIRE) — Mondelēz International has announced today that it will source plastic linked to advanced recycling technology (also known as chemical or molecular recycling) for the production of packaging across the majority of SKUs for its Triscuit Crackers in the U.S. and Canada. Triscuit is an iconic snacking brand with a history and heritage dating back more than a century. Through this initiative, the Triscuit brand is contributing to the sourcing of recycled plastics via the ISCC mass balance approach, helping to support a more circular pack economy in the U.S. and Canada. This contributes to Mondelēz International’s goal of achieving about 5% recycled plastic content by 2025**. In the past,...

Onychomycosis Market Forecast to Grow at 4.7% CAGR from 2024 to 2031 | SkyQuest Technology

Written by Customer Service on September 18, 2024. Posted in Mergers And Acquisitions.

Key driver of the global onychomycosis market is the increasing prevalence of risk factors such as diabetes, aging population, weakened immune systems, and nail trauma. Westford, USA, Sept. 18, 2024 (GLOBE NEWSWIRE) — Onychomycosis Market size was valued at USD 3.5 billion in 2023 to USD 5.05 billion by 2031, at a CAGR of 4.7% during the forecast period (2024-2031). The global onychomycosis treatment market refers to the pharmaceutical and healthcare industry focused on the diagnosis, treatment and management of the fungal infection that affects the nails, commonly known as onychomycosis. Onychomycosis is a common disease that can cause nail discoloration, hardened and weakened. Increased awareness of nails health due to possible complications and complications, increasing incidence of onychomycosis due to factors such as aging...

Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer

Written by Customer Service on September 18, 2024. Posted in Mergers And Acquisitions.

– Transaction Will Maximize the Access and Uptake of COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent – – G1 Stockholders to Receive U.S. $7.15 Per Share in Cash – HOLBAEK, Denmark and RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2024 (GLOBE NEWSWIRE) — Pharmacosmos A/S, a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, and G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company focused on delivering next-generation therapies that improve the lives of those affected by cancer, today announced that Pharmacosmos A/S has successfully completed the previously announced tender offer to acquire all outstanding shares of G1 Therapeutics for U.S. $7.15 per share net to the holder in cash,...

Form 8.3 – [ECKOH PLC – 17 09 2024] – (CGWL)

Written by Customer Service on September 18, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree ECKOH PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing...

Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

Written by Customer Service on September 18, 2024. Posted in Public Companies.

SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold’ tumors ‘hot’ Topline safety data of SB101 Phase 1 study expected by Q4 2024 PRINCETON, NJ, Sept. 18, 2024 (GLOBE NEWSWIRE) — Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced the completion of enrollment and initiation of dosing in its Phase 1 SB101 clinical trial of SON-1010 (IL12-FHAB) in adult patients with advanced solid tumors. The Company expects to report topline data from this study in Q4 2024. Pankaj Mohan, Founder and Chief Executive Officer of Sonnet commented, “This milestone is an important step forward in our development program for SON-1010 as a monotherapy. We are encouraged by the data seen to date demonstrating safety...

Femasys Announces Infertility Clinic Customers from Coast to Coast

Written by Customer Service on September 18, 2024. Posted in Public Companies.

Leading medical clinics become key regional resources to offer FemaSeed infertility treatment ATLANTA, Sept. 18, 2024 (GLOBE NEWSWIRE) — Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces the onboarding of the first infertility medical clinic customers to offer its FemaSeed infertility treatment to patients in California and Florida. “Femasys has begun partnering with infertility centers across the United States, enabling them to offer FemaSeed to their patients. We are excited to welcome Reproductive Fertility Center and Palm Beach Fertility Center as our first customers,” said Femasys CEO Kathy Lee-Sepsick. “We are enthusiastic about expanding...

Southern Florida Greets Newest Del Taco with Warm Welcome

Written by Customer Service on September 18, 2024. Posted in Public Companies.

Del Taco continues Florida expansion with first location in Charlotte County, marking the leading Mexican QSR chain’s 12th location in the state PORT CHARLOTTE, Fla., Sept. 18, 2024 (GLOBE NEWSWIRE) — Del Taco, the nation’s second-largest Mexican quick service restaurant,* announced the opening of the newest location at 19001 Murdock Circle, Port Charlotte, Florida. This is the brand’s first location in Port Charlotte and the third location for the franchisees that brought Del Taco’s bold flavors and sleek design to Bradenton. Featuring Del Taco’s sleek, contemporary Fresh Flex layout, the Port Charlotte restaurant invites customers to “Go Bold” with a fresh, vibrant interior design, and its open-layout kitchen brings to life the brand’s commitment to freshness. For orders on the go, Del Taco guests can breeze through the drive-thru...

StorageVault Completes Purchase for $71,500,000

Written by Customer Service on September 18, 2024. Posted in Mergers And Acquisitions.

TORONTO, Sept. 18, 2024 (GLOBE NEWSWIRE) — STORAGEVAULT CANADA INC. (“StorageVault”) (SVI-TSX) is pleased to announce that it has completed the acquisition of the two adjacent properties, located in Toronto, ON announced on July 16, 2024 for an aggregate purchase price of $71,500,000 (the “Acquisition”). The total purchase price of the Acquisition, subject to customary adjustments, was paid with a mortgage and funds on hand. About StorageVault Canada Inc.StorageVault currently owns and operates 249 storage locations across Canada. StorageVault owns 219 of these locations plus over 5,000 portable storage units representing over 12.4 million rentable square feet on over 715 acres of land. StorageVault also provides last mile storage and logistics’ solutions and professional records management services, ‎such as document and media...

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Written by Customer Service on September 18, 2024. Posted in Mergers And Acquisitions.

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis Proposed acquisition extends Organon’s international dermatology capabilities to the U.S. BASEL, Switzerland and LONDON and NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) — Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, and Dermavant Sciences Ltd. announced today that they have entered into a definitive agreement, under which Organon will acquire Dermavant, a Roivant (NASDAQ: ROIV) company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Dermavant’s novel product, VTAMA® (tapinarof) cream, 1%, for the topical treatment of mild, moderate,...

WillScot and McGrath RentCorp Mutually Agree to Terminate Previously Announced Combination

Written by Customer Service on September 18, 2024. Posted in Mergers And Acquisitions.

WillScot Remains Focused on Executing $1 Billion of Idiosyncratic Growth Opportunities Board Increases Share Repurchase Authorization to $1 Billion PHOENIX, Sept. 18, 2024 (GLOBE NEWSWIRE) — WillScot Holdings Corporation (“WillScot” or the “Company”) (Nasdaq: WSC), a leader in innovative temporary flexible space solutions, today announced that it has entered into an agreement with McGrath RentCorp (“McGrath”) (Nasdaq: MGRC) to terminate the companies’ previously announced merger, pursuant to the terms of the January 28, 2024 merger agreement, under which WillScot would have acquired McGrath for a mix of cash and stock consideration. Although both companies continue to believe in the merits and procompetitive benefits of the combination, WillScot and McGrath mutually agreed to terminate the transaction based on a joint determination...

Day: September 18, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice